CA
NZ
UK
AU
IND
US
…
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 23906.15M | 11539.81M | 11831.99M | 10618.48M | 6015.61M |
| Minority interest | -182.48M | -117.43M | -93.51M | -88.90M | -38.79M |
| Net income | 19150.58M | 9450.31M | 9606.75M | 8813.71M | 5097.16M |
| Selling general administrative | 680.68M | 759.20M | 905.56M | 927.22M | 766.15M |
| Selling and marketing expenses | 249.95M | 210.51M | 188.00M | 731.59M | 698.97M |
| Gross profit | 21654.73M | 16276.92M | 16574.99M | 14677.56M | 8310.13M |
| Reconciled depreciation | 3473.88M | 2782.18M | 2283.57M | 1693.48M | 1285.76M |
| Ebit | 24212.64M | 11755.85M | 11885.60M | 11080.89M | 5953.02M |
| Ebitda | 27686.53M | 14538.02M | 14169.17M | 12774.37M | 7238.78M |
| Depreciation and amortization | 3473.88M | 2782.18M | 2283.57M | 1693.48M | 1285.76M |
| Operating income | 17004.94M | 11580.17M | 11872.29M | 10652.25M | 6037.73M |
| Other operating expenses | 28451.22M | 27661.26M | 28468.52M | 29606.51M | 18242.66M |
| Interest expense | 306.49M | 216.03M | 74.82M | 159.84M | 128.33M |
| Tax provision | 4573.09M | 1972.07M | 2131.73M | 1715.87M | 879.66M |
| Interest income | 938.02M | 626.76M | 444.47M | 190.85M | 191.69M |
| Net interest income | 615.53M | 386.07M | 229.67M | -15.55M | 55.15M |
| Income tax expense | 4573.09M | 1972.07M | 2131.73M | 1715.87M | 879.66M |
| Total revenue | 45456.17M | 39241.43M | 40340.81M | 39354.78M | 22902.39M |
| Total operating expenses | 4649.79M | 4696.74M | 4739.72M | 4929.29M | 3650.40M |
| Cost of revenue | 23801.44M | 22964.52M | 23765.81M | 24677.22M | 14592.26M |
| Total other income expense net | 6901.21M | -40.36M | -40.29M | -33.77M | -22.12M |
| Net income from continuing ops | 19333.07M | 9567.74M | 9700.26M | 8902.61M | 5135.95M |
| Net income applicable to common shares | - | - | - | 8813.71M | 5097.16M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 103120.97M | 80325.82M | 73669.35M | 64690.33M | 55127.39M |
| Intangible assets | 1280.52M | 1574.80M | 1863.80M | 1784.83M | 1599.75M |
| Other current assets | 3270.88M | 4577.31M | 2213.09M | 2649.78M | 1001.97M |
| Total liab | 22873.26M | 21240.21M | 18151.90M | 17763.65M | 16369.93M |
| Total stockholder equity | 79712.29M | 58632.71M | 55122.45M | 46589.95M | 38491.51M |
| Deferred long term liab | - | - | - | 1810.85M | 1539.45M |
| Other current liab | 8036.79M | 12008.35M | 8452.02M | 8738.50M | 8395.68M |
| Common stock | 2983.76M | 2887.99M | 2968.84M | 2960.53M | 2955.83M |
| Capital stock | 2983.76M | 2887.99M | 2968.84M | 2960.53M | 2955.83M |
| Retained earnings | 46148.65M | 33365.08M | 26796.82M | 19136.48M | 12126.08M |
| Other liab | - | - | - | 1499.40M | 1759.21M |
| Good will | 864.39M | 972.35M | 1820.87M | 1822.10M | 1925.56M |
| Other assets | - | 0.00M | 0.00M | 3347.30M | 1994.38M |
| Cash | 35131.31M | 18322.03M | 13764.06M | 7985.74M | 8238.77M |
| Total current liabilities | 19235.27M | 16226.11M | 14756.30M | 14499.36M | 12984.59M |
| Current deferred revenue | - | - | 1955.36M | - | - |
| Net debt | -26870.81M | -13573.27M | -8311.43M | -2119.30M | -3954.75M |
| Short term debt | 5986.14M | 1242.69M | 3667.06M | 4101.55M | 2657.90M |
| Short long term debt | 5986.14M | 1242.69M | 3667.06M | 3874.12M | 2261.48M |
| Short long term debt total | 8260.50M | 4748.76M | 5452.63M | 5866.44M | 4284.02M |
| Other stockholder equity | 30579.88M | 22078.76M | 25244.48M | 24492.95M | 23409.60M |
| Property plant equipment | - | - | - | 23581.61M | 16128.74M |
| Total current assets | 61677.06M | 38690.15M | 30422.47M | 23997.23M | 21985.65M |
| Net tangible assets | - | - | - | 42983.02M | 34966.19M |
| Short term investments | 5806.21M | 1233.98M | 11.00M | 2.00M | 527.29M |
| Net receivables | 8475.41M | 9157.08M | 9155.97M | 7691.11M | 6312.61M |
| Long term debt | 1819.10M | 2959.51M | 687.02M | 781.08M | 607.14M |
| Inventory | 8993.25M | 5399.75M | 4736.23M | 5668.59M | 5905.01M |
| Accounts payable | 2449.52M | 1764.44M | 1645.32M | 1659.31M | 1931.01M |
| Accumulated other comprehensive income | 352.87M | 300.89M | 112.31M | - | - |
| Non currrent assets other | 1846.52M | 2929.47M | 1181.65M | 3795.17M | 4966.23M |
| Non current assets total | 41443.91M | 41635.67M | 43246.88M | 40693.10M | 33141.74M |
| Capital lease obligations | 455.26M | 546.56M | 1098.55M | 983.82M | 1018.98M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 615.19M | -5518.18M | -7560.53M | -9690.29M | 2765.63M |
| Change to liabilities | - | - | - | 1227.11M | 3616.44M |
| Total cashflows from investing activities | -1945.11M | -5518.18M | -7560.53M | -9690.29M | -4838.95M |
| Net borrowings | 3562.60M | 3319.76M | 178.21M | 1667.96M | 825.38M |
| Total cash from financing activities | 1123.54M | -3832.19M | -3941.38M | -1277.81M | -1723.91M |
| Change to operating activities | - | - | - | 882.75M | 556.62M |
| Net income | 19333.07M | 9567.74M | 9606.75M | 8902.61M | 5135.95M |
| Change in cash | 16011.12M | 3443.67M | 2017.13M | -191.43M | -2052.72M |
| Begin period cash flow | 13444.71M | 10001.04M | 7983.90M | 8175.34M | 10228.06M |
| End period cash flow | 29455.83M | 13444.71M | 10001.04M | 7983.90M | 8175.34M |
| Total cash from operating activities | 17203.16M | 12406.51M | 13386.91M | 10616.03M | 4589.29M |
| Depreciation | 3473.88M | 2782.18M | 2283.57M | 1693.48M | 1285.76M |
| Other cashflows from investing activities | 75.12M | 15.84M | 395.09M | 57.60M | 187.38M |
| Dividends paid | 4968.58M | 3084.88M | 2755.79M | 1598.43M | 912.74M |
| Change to inventory | -3662.12M | -914.17M | 977.63M | 498.86M | -2991.68M |
| Change to account receivables | -229.62M | -779.19M | -2140.60M | -1978.91M | -1833.13M |
| Sale purchase of stock | - | -3908.91M | -1182.21M | - | - |
| Other cashflows from financing activities | 2529.53M | -158.17M | -1363.81M | 1984.67M | 398.37M |
| Change to netincome | - | - | - | -833.06M | -1336.06M |
| Capital expenditures | 5538.15M | 4003.49M | 5516.56M | 9965.69M | 6936.09M |
| Change in working capital | -291.88M | -970.38M | -406.97M | -252.94M | -1208.37M |
| Stock based compensation | - | - | 750.33M | - | - |
| Other non cash items | -5311.91M | 1026.97M | 1903.56M | 272.88M | -624.04M |
| Free cash flow | 11665.01M | 8403.02M | 7870.35M | 650.34M | -2346.80M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| WUXAY WuXi AppTec Co. Ltd |
0.04 0.16% |
24.29 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
| TMO Thermo Fisher Scientific Inc |
5.03 0.71% |
709.18 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
2.91 1.24% |
236.98 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
23.25 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| NTRA Natera Inc |
11.58 2.73% |
436.00 | - | 5000.00 | 18.68 | 27.76 | 18.36 | -26.80 |
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
| Name | Title | Year Born |
|---|---|---|
| Dr. Ge Li Ph.D. | Co-Founder, Chairman, Pres & CEO | 1967 |
| Dr. Minzhang Chen Ph.D. | Co-Chief Exec. Officer & Exec. Director | 1970 |
| Dr. Qing Yang Ph.D. | Co-CEO & Exec. Director | 1970 |
| Dr. Edward Hu M.B.A. | Vice Chairman & Global Chief Investment Officer | 1963 |
| Ms. Ming Shi | Sr. VP & CFO | 1975 |
| Dr. Shuhui Chen Ph.D. | Chief Scientific Officer & Exec. VP | 1964 |
| Mr. Kyler Lei | IR Director | NA |
| Mr. Yao Chi | Joint Company Sec. & Exec. Director of the Corp. Legal Office | 1983 |
| Dr. Howard Wu J.D. | Sr. VP, Gen. Counsel & Global Head of HR | NA |
| Mr. Zhaohui Zhang | COO of China, Exec. VP & Director | 1970 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.52%
Communication Services
+0.32%
Consumer Cyclical
+1.01%
Consumer Defensive
+0.00%
Energy
+0.01%
Financial Services
+0.62%
Financials
-2.62%
Healthcare
+0.51%
Industrials
+0.71%
Real Estate
+0.72%
Technology
-0.46%
Utilities
+0.54%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...